BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The Collaborative - ECPv6.15.12.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://traininghealthequity.org
X-WR-CALDESC:Events for The Collaborative
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20230428T120000
DTEND;TZID=UTC:20230428T130000
DTSTAMP:20260423T155456
CREATED:20230420T171923Z
LAST-MODIFIED:20230420T171923Z
UID:6352-1682683200-1682686800@traininghealthequity.org
SUMMARY:HIV Learning Network: HIV and Primary Care Update: Diabetes Medications
DESCRIPTION:Register \n\n\n\n\nJoin us for the next HIV Learning Network session on April 27 @ 12:00pm (Pacific) for HIV and Primary Care Update: Diabetes Medications\, by Kirsten Balano\, PharmD\, AAHIVP\, HIVLN Faculty\, Pacific AETC Pharmacy Lead\, Associate Professor of Clinical Pharmacy\, UCSF. \nDescription: The number of people living with HIV and AIDS (PWHA) reached to almost 40 million\, half of which are under antiretroviral treatment (ART). Although the introduction of this therapy significantly improved the life span and quality of PWHA\, metabolic complications of these people remains to be an important issue. These metabolic complications include hyperlipidemia\, abnormal fat redistribution and diabetes mellitus\, which are defined as lipodystrophy syndrome. (Culha MG\, et al. Med Hypotheses. 2016) Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity. In this session\, Dr. Kirsten Balano\, PharmD\, AAAHIVP\, will review these class of drugs and discuss their benefits and precautions for treating HIV-associated metabolic adverse effects\, and therefore improve the quality and length of life in people with HIV. \nLearning Objectives:\nUpon completion of this session\, participants will be able to: \n\nDescribe the value of Glucogon-like-protein-1 Receptor Agonists (GLP-1RA) for weight loss.\nApply updated diabetes standards to patients with HIV and Diabetes Type 2.\nInvestigate resources to access to GLP1RA for patients with HIV.\n\nPhysicians:\nThis activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nevada School of Medicine and the Pacific AIDS Education and Training Center. The University of Nevada\, Reno School of Medicine is accredited by the ACCME to provide continuing medical education to physicians.The University of Nevada\, Reno School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nNurses:\nNurses may receive continuing education credit for this educational activity as the ANCC accepts AMA PRA Category 1 Credits™ through its reciprocity agreement. \nHIV Learning Network offers free CME for participants attending sessions\, pending completion of the post-session evaluation. \n\n\n\n\n\n\nPresented By:\nPacific AETC Regional Office\n\n\nContact Email:\nbrian.abascal@ucsf.edu\n\n\nContact Number:\n(415) 476-2434\n\n\nEvent Type:\nDistance based learning
URL:https://traininghealthequity.org/event/hiv-learning-network-hiv-and-primary-care-update-diabetes-medications/
LOCATION:Zoom
END:VEVENT
END:VCALENDAR